medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 05

<< Back Next >>

Med Int Mex 2024; 40 (05)

IgG4-related cholangitis

García FW, Villafuerte TI, Mexia AAL, Prado HD

Language: Spanish
References: 47
Page: 295-304
PDF size: 397.15 Kb.


ABSTRACT

Background: Cholangitis is a fibroinflammatory disease, almost always due to obstructive jaundice, which is difficult to differentiate from primary sclerosing cholangitis by imaging; its diagnosis is based on elevated serum IgG4 concentrations and histopathological data.
Objective: To describe the concept and current classification of SC-IgG4 according to different associations, as well as the pathogenic, epidemiological, clinical and therapeutic aspects.
Methodology: Bibliographic search in the databases GoogleScholar, PubMed, Medline LILACS and Scopus, articles in English and Spanish were included.
Results: From the bibliographic review, 60 articles were obtained that met the inclusion criteria, of which 13 were discarded due to several reasons (letters to the editor, case reports and duplicate reviews). To date there are no unified criteria in relation to the diagnosis, classification and management of SC-IgG4. Similarities and differences in relation to the diagnostic criteria of SC-IgG4 between the Endoscopy Society of Japan and the Gastroenterology Societies of Europe and the United States were found. A significant proportion of SC-IgG4 cases present high levels of IgG4 in the blood and usually respond satisfactorily to corticosteroids.
Conclusions: IgG4-related sclerosing cholangitis is a biliary manifestation of the disease related to IgG4, it is very difficult to diagnose and is often confused with cholangiocarcinoma and other types of cholangitis. IgG4-related sclerosing cholangitis has a very good prognosis and responds satisfactorily to corticosteroids.


REFERENCES

  1. Umehara H, Okazaki K, Masaki Y, Kawano M, et al. Comprehensivediagnostic criteria for IgG4-related disease(IgG4-RD), 2011. Mod Rheumatol 2012; 22 (1): 21-30. doi:10.1007/s10165-011-0571-z

  2. Okazaki K, Uchida K, Ikeura T, Takaoka M. Current conceptand diagnosis of IgG4-related disease in the hepato-biliopancreaticsystem. J Gastroenterol 2013; 48 (3): 303-14.doi: 10.1007/s00535-012-0744-3

  3. Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnosticcriteria of IgG4-related sclerosing cholangitis 2012. J HepatobiliaryPancreat Sci 2012; 19 (5): 536-542. doi:10.1007/s00534-012-0521-y

  4. Nakazawa T, Kamisawa T, Okazaki K, Kawa S, et al. Clinicaldiagnostic criteria for IgG4-related sclerosing cholangitis2020: (Revision of the clinical diagnostic criteria forIgG4-related sclerosing cholangitis 2012). J HepatobiliaryPancreat Sci 2021; 28 (3): 235-242. doi: 10.1002/jhbp.913

  5. Ghazale A, Chari ST, Zhang L, Smyrk TC, et al. ImmunoglobulinG4-associated cholangitis: clinical profile and responseto therapy. Gastroenterology 2008; 134 (3): 706-15. doi:10.1053/j.gastro.2007.12.009

  6. Hirano K, Tada M, Isayama H, Yamamoto K, et al.Endoscopic evaluation of factors contributing to intrapancreaticbiliary stricture in autoimmune pancreatitis.Gastrointest Endosc 2010; 71 (1): 85-90. doi: 10.1016/j.gie.2009.08.008

  7. Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosingcholangitis with and without hepatic inflammatory pseudotumor,and sclerosing pancreatitis-associated sclerosingcholangitis: ¿do they belong to a spectrum of sclerosingpancreatitis? Am J Surg Pathol 2004; 28 (9): 1193-1203.doi: 10.1097/01.pas.0000136449.37936.6c

  8. Naitoh I, Kamisawa T, Tanaka A, et al. Clinical characteristicsof immunoglobulin IgG4-related sclerosing cholangitis:Comparison of cases with and without autoimmunepancreatitis in a large cohort. Dig Liver Dis 2021; 53 (10):1308-1314. doi: 10.1016/j.dld.2021.02.009

  9. Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K,Takikawa H. Nationwide survey for primary sclerosingcholangitis and IgG4-related sclerosing cholangitis inJapan. J Hepatobiliary Pancreat Sci 2014; 21 (1): 43-50.doi:10.1002/jhbp.50

  10. Kanno A, Masamune A, Okazaki K, et al. Nationwide epidemiologicalsurvey of autoimmune pancreatitis in Japanin 2011. Pancreas 2015; 44 (4): 535-539. doi:10.1097/MPA.0000000000000325

  11. Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practiceguidelines for IgG4-related sclerosing cholangitis. J HepatobiliaryPancreat Sci 2019; 26 (1): 9-42. doi:10.1002/jhbp.596

  12. Tanaka A, Mori M, Kubota K, et al. Epidemiological featuresof immunoglobulin G4-related sclerosing cholangitis inJapan. J Hepatobiliary Pancreat Sci 2020; 27 (9): 598-603.doi:10.1002/jhbp.793

  13. Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S,Takikawa H. Increase trend in the prevalence and maleto-female ratio of primary biliary cholangitis, autoimmunehepatitis, and primary sclerosing cholangitis in Japan.Hepatol Res 2019; 49 (8): 881-889. doi:10.1111/hepr.13342

  14. Tanaka A, Tazuma S, Okazaki K, et al. Clinical features,response to treatment, and outcomes of IgG4-relatedsclerosing cholangitis. Clin Gastroenterol Hepatol 2017; 15(6): 920-926.e3. doi: 10.1016/j.cgh.2016.12.038

  15. Manganis CD, Chapman RW, Culver EL. Review of primarysclerosing cholangitis with increased IgG4 levels. WorldJ Gastroenterol 2020; 26 (23): 3126-3144. doi:10.3748/wjg. v26.i23.3126

  16. Okazaki K, Uchida K, Ohana M, et al. Autoimmune-relatedpancreatitis is associated with autoantibodies and aTh1/Th2-type cellular immune response. Gastroenterology2000; 118 (3): 573-581. doi:10.1016/s0016-5085(00)70264-2

  17. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S,Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.Medicine (Baltimore) 2012; 91 (1): 57-66. doi: 10.1097/MD.0b013e3182431ef6

  18. Zhao EJ, Cheng CV, Mattman A, Chen LYC. Polyclonal hypergammaglobulinaemia:assessment, clinical interpretation,and management. Lancet Haematol 2021; 8 (5): e365-e375.doi:10.1016/S2352-3026(21)00056-9

  19. Zen Y, Kawakami H, Kim JH. IgG4-related sclerosing cholangitis:all we need to know. J Gastroenterol 2016; 51 (4):295-312. doi:10.1007/s00535-016-1163-7

  20. Okazaki K, Uchida K, Miyoshi H, Ikeura T, Takaoka M, NishioA. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allergy Immunol 2011; 41 (2):126-138. doi:10.1007/s12016-010-8214-2

  21. Wallace ZS, Naden RP, Chari S, Choi HK, et al; Membersof the ACR/EULAR IgG4-RD Classification Criteria WorkingGroup. The 2019 American College of Rheumatology/EuropeanLeague Against Rheumatism classification criteria forIgG4-related disease. Ann Rheum Dis 2020; 79 (1): 77-87.doi: 10.1136/annrheumdis-2019-216561

  22. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response totherapy. Gastroenterology 2008; 134 (3): 706-715. doi:10.1053/j.gastro.2007.12.009

  23. Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmunepancreatitis and IgG4-related sclerosing cholangitis is associatedwith extrapancreatic organ failure, malignancy, andmortality in a prospective UK cohort. Am J Gastroenterol2014; 109 (10): 1675-1683. doi:10.1038/ajg.2014.223

  24. Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinicalphenotypes of IgG4-related disease reflect different prognosticoutcomes. Rheumatology (Oxford) 2020; 59 (9):2435-2442. doi:10.1093/rheumatology/keaa221

  25. Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer inpatients with autoimmune pancreatitis. Am J Gastroenterol2013; 108 (4): 610-617. doi:10.1038/ajg.2012.465

  26. Moon SH, Kim MH, Lee JK, et al. Development of a scoringsystem for differentiating IgG4-related sclerosing cholangitisfrom primary sclerosing cholangitis. J Gastroenterol2017; 52 (4): 483-493. doi:10.1007/s00535-016-1246-5

  27. Nakazawa T, Ohara H, Sano H, et al. Cholangiographycan discriminate sclerosing cholangitis with autoimmunepancreatitis from primary sclerosing cholangitis. GastrointestEndosc 2004; 60 (6): 937-944. doi:10.1016/s0016-5107(04)02229-1

  28. Drazilova S, Veseliny E, Lenartova PD, Drazilova D, et al.IgG4-related sclerosing cholangitis: Rarely diagnosed, butnot a rare disease. Can J Gastroenterol Hepatol 2021; 2021:1959832. doi: 10.1155/2021/1959832

  29. Naitoh I, Nakazawa T, Ohara H, et al. Endoscopic transpapillaryintraductal ultrasonography and biopsy in the diagnosisof IgG4-related sclerosing cholangitis. J Gastroenterol 2009;44 (11): 1147-1155. doi:10.1007/s00535-009-0108-9

  30. Naitoh I, Nakazawa T, Hayashi K, et al. Comparison ofintraductal ultrasonography findings between primarysclerosing cholangitis and IgG4-related sclerosing cholangitis.J Gastroenterol Hepatol 2015;30(6):1104-1109.doi:10.1111/jgh.12894

  31. Naitoh I, Nakazawa T. Classification and DiagnosticCriteria for IgG4-Related Sclerosing Cholangitis.Gut Liver.2022;2022;16(1): 28-36.doi:10.5009/gnl210116

  32. Culver EL,Sadler Simpson D,et al.Elevated Serum IgG4 Levelsin Diagnosis, Treatment Response,Organ Involvement,andRelapse in a Prospective IgG4-Related Disease UK Cohort.Am J Gastroenterol.2016;111(5)733-743.doi:10.1038/ajg.2016.40

  33. Taghavi SA, Majd SK, Sianati M, Sepehrimanesh M. Prevalenceof IgG-4-associated cholangiopathy based on serumIgG-4 levels in patients with primary sclerosing cholangitisand its relationship with inflammatory bowel disease.Turk J Gastroenterol 2016; 27 (6): 547-552. doi:10.5152/tjg.2016.16344

  34. Tanaka A, Tazuma S, Nakazawa T, et al. No negative impactof serum IgG4 levels on clinical outcome in 435 patientswith primary sclerosing cholangitis from Japan HepatobiliaryPancreat Sci 2017; 24 (4): 217-225. doi:10.1002/jhbp.432

  35. Muir AJ,Levy C,Janssen HLA,et al.Simtuzumb for PrimarySclerosing Cholangitis:Phase 2 Study Results With Insinghtson the Nature History of the Disease.Hepatology2019;69(2):684-698.doi:10.1002/hep.30237

  36. Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serumimmunoglobulin G4 in distinguishing immunoglobulin G4associated cholangitis from cholangiocarcinoma. Hepatology2011; 54 (3): 940-948. doi:10.1002/hep.24487

  37. Ohara H, Nakazawa T, Kawa S, et al. Establishment of aserum IgG4 cut-off value for the differential diagnosisof IgG4-related sclerosing cholangitis: a Japanese cohort.J Gastroenterol Hepatol 2013; 28 (7): 1247-1251.doi:10.1111/jgh.12248

  38. Vosskuhl K, Negm AA, Frame T, et al. Measurement ofIgG4 in bile: A new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy 2012; 44 (1): 48-52.doi:10.1055/s-0030-1256872

  39. Nishino T, Oyama H, Hashimoto E, et al. Clinicopathologicaldifferentiation between sclerosing cholangitis withautoimmune pancreatitis and primary sclerosing cholangitis.J Gastroenterol 2007; 42 (7): 550-559. doi:10.1007/s00535-007-2038-8

  40. Deshpande V, Sainani NI, Chung RT, et al. IgG4-associatedcholangitis: a comparative histological and immunophenotypicstudy with primary sclerosing cholangitis on liverbiopsy material. Mod Pathol 2009; 22 (10): 1287-1295.doi:10.1038/modpathol.2009.94

  41. Löhr JM, Beuers U, Vujasinovic M, et al. EuropeanGuideline on IgG4-related digestive disease- UEG and SGF evidence-based recommendations.United European Gastroenterol J 2020; 8 (6): 637-666.doi:10.1177/2050540620934911

  42. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standardsteroid treatment for autoimmune pancreatitis. Gut 2009;58 (11): 1504-1507.doi10.1136/gut.2008.172908

  43. Matsubachachi H, Ishiwatari H, Imai K, et al. Steroid therapyand steroid response in autoimmune pancreatitis. Int J MolSci 2019; 21 (1): 257. doi:10.3390/ijms21010257

  44. Masaki Y, Shimizu H, Sato Nakamura T, et al. IgG4-relateddisease: diagnostic methods and therapeutic strategiesin Japan. J Clin Exp Hematop 2014; 54 (2): 95-101.doi:10.3960/jsIrt.54.95

  45. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsingautoimmune pancreatitis with immunomodulatorsand rituximab: the Mayo Clinic experience. Gut 2013; 62(11): 1607-1615. doi:10.1136/gutjnl-2012-302886

  46. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximabfor IgG4-related disease: a prospective, open-labeltrial. Ann Rheum Dis 2015; 74 (6): 1171-1177. doi:10.1136/annrheumdis-2014-206605

  47. Bi Y, Hart PA, Law R, et al. Obstructive jaundice in autoimmunepancreatitis can be safely treated with corticosteroidsalone without biliary stenting. Pancreatology 2016; 16(3): 391-396. doi: 10.1016/j.pan.2016.03.017




2020     |     www.medigraphic.com